Avidity biosciences reports second quarter 2023 financial results and recent highlights

Advancing three clinical development programs – dm1, dmd, fshd - with data anticipated from each program over the next 12 months san diego , aug. 8, 2023 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today reported financial results and recent highlights for the second quarter ended june 30, 2023. avidity ended the second quarter of 2023 with cash, cash equivalents and marketable securities totaling $577 million.
RNA Ratings Summary
RNA Quant Ranking